Floatz logo

INTERFERON ALFA-2B

Peripheral Neuropathy

University Hospital, Bordeauxprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Peripheral Neuropathy cohort.

Asset / SponsorPhaseRating
LIDOCAINE
University of Utah
Phase 4BBB
Nabiximols
VA Office of Research and Development
Phase 3BBB
Nabilone
NEMA Research, Inc.
Phase 4BB
Duloxetine
University of Rochester
Phase 3BB
cc-5013
Tanta University
Phase 4BB

View all 33 →

Same molecule, other indications

INTERFERON ALFA-2B is also rated in:

melanomaDormant
BB
Indicative ·
68 / 100
View asset →
renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
Stage IV Renal Cell CancerDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →